Cerebrospinal fluid endocannabinoid levels in Gilles de la Tourette syndrome

0
84

  • 1.

    Müller-Vahl KR, Kolbe H, Schneider U, Emrich HM. Cannabinoids: possible role in patho-physiology and therapy of Gilles de la Tourette syndrome. Acta Psychiatr Scand. 1998;98:502–6.

    PubMed 

    Google Scholar
     

  • 2.

    Abi-Jaoude E, Chen L, Cheung P, Bhikram T, Sandor P. Preliminary evidence on cannabis effectiveness and tolerability for adults with Tourette syndrome. J Neuropsychiatry Clin Neurosci. 2017;29:391–400.

    PubMed 

    Google Scholar
     

  • 3.

    Jakubovski E, Müller-Vahl K. Speechlessness in Gilles de la Tourette sndrome: cannabis-based medicines improve severe vocal blocking tics in two patients. Int J Mol Sci. 2017;18: pii: E1739.

  • 4.

    Kanaan AS, Jakubovski E, Müller-Vahl K. Significant tic reduction in an otherwise treatment-resistant patient with Gilles de la Tourette syndrome following treatment with nabiximols. Brain Sci. 2017;7: pii: E47.

  • 5.

    Trainor D, Evans L, Bird R. Severe motor and vocal tics controlled with Sativex®. Australas Psychiatry. 2016. https://doi.org/10.1177/1039856216663737.

  • 6.

    Szejko N, Jakubovski E, Fremer C, Kunert K, Müller-Vahl K. Delta-9-tetrahydrocannabinol for the treatment of a child with Tourette syndrome—case report. Eur J Med Case Rep. 2018;2:43–6.


    Google Scholar
     

  • 7.

    Hasan A, Rothenberger A, Münchau A, Wobrock T, Falkai P, Roessner V. Oral delta 9-tetrahydrocannabinol improved refractory Gilles de la Tourette syndrome in an adolescent by increasing intracortical inhibition: a case report. J Clin Psychopharmacol. 2010;30:190–2.

    PubMed 

    Google Scholar
     

  • 8.

    Müller-Vahl KR, Schneider U, Koblenz A, Jöbges M, Kolbe H, Daldrup T, et al. Treatment of Tourette’s syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry. 2002;35:57–61.

    PubMed 

    Google Scholar
     

  • 9.

    Müller-Vahl KR, Schneider U, Prevedel H, Theloe K, Kolbe H, Daldrup T, et al. Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J Clin Psychiatry. 2003;64:459–65.

    PubMed 

    Google Scholar
     

  • 10.

    Fernández-Ruiz J. The endocannabinoid system as a target for the treatment of motor dysfunction. Br J Pharm. 2009;156:1029–40.


    Google Scholar
     

  • 11.

    Bindila L, Lutz B. Extraction and simultaneous quantification of endocannabinoids and endocannabinoid-like lipids in biological tissues. Methods Mol Biol. 2016;1412:9–18.

    CAS 
    PubMed 

    Google Scholar
     

  • 12.

    Baumgaertel C, Skripuletz T, Kronenberg J, Stangel M, Schwenkenbecher P, Sinke C, et al. Immunity in Gilles de la Tourette-Syndrome: results from a cerebrospinal fluid study. Front Neurol. 2019;10:732.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 13.

    Leckman JF, Riddle MA, Hardin MT, Ort SI, Swartz KL, Stevenson J, et al. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry. 1989;28:566–73.

    CAS 
    PubMed 

    Google Scholar
     

  • 14.

    Woods DW, Piacentini J, Himle MB, Chang S. Premonitory Urge for Tics Scale (PUTS): initial psychometric results and examination of the premonitory urge phenomenon in youths with Tic disorders. J Dev Behav Pediatr. 2005;26:397–403.

    PubMed 

    Google Scholar
     

  • 15.

    Cavanna AE, Schrag A, Morley D, Orth M, Robertson MM, Joyce E, et al. The Gilles de la Tourette syndrome-quality of life scale (GTS-QOL): development and validation. Neurology. 2008;71:1410–6.

    CAS 
    PubMed 

    Google Scholar
     

  • 16.

    Beck AT, Steer RA, Brown GK. Manual for the beck depression inventory-II. San Antonio, TX: Psychological Corporation; 1993.

  • 17.

    Conners CK, Erhardt D, Sparrow E. Conners’ Adult ADHD Rating Scales (CAARS) technical manual. New York: Multihealth Systems, Inc., 1999.

  • 18.

    American Psychiatric Association. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Text Revision. Washington: American Psychiatric Association; 2000.

  • 19.

    Retz-Junginger P, Retz W, Blocher D, Weijers H-G, Trott G-E, Wender PH, et al. Wender Utah Rating Scale (WURS-k) Die deutsche Kurzform zur retrospektiven Erfassung des hyperkinetischen Syndroms bei Erwachsenen. Nervenarzt 2002;73:830–8.

    CAS 
    PubMed 

    Google Scholar
     

  • 20.

    Beck AT, Steer RA. Beck anxiety inventory manual. San Antonio, TX: Psychological Corporation. 1993.

  • 21.

    Goodman WK, Price LH, Rasmussen R. The Yale-Brown obsessive compulsive scale: I. development, use, and reliability. Arch Gen Psychiatry. 1989;46:1006–11.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 22.

    Franke G. Brief symptom inventory von L. R. Derogatis (Kurzform der SCL-90-R). Göttingen: Beltz. 2000.

  • 23.

    Kranaster L, Hoyer C, Aksay SS, Bumb JM, Leweke FM, Janke C, et al. Electroconvulsive therapy enhances endocannabinoids in the cerebrospinal fluid of patients with major depression: a preliminary prospective study. Eur Arch Psychiatry Clin Neurosci. 2017;267:781–6.

    PubMed 

    Google Scholar
     

  • 24.

    Lerner R, Lutz B, Bindila L. Tricks and tracks in the identification and quantification of endocannabinoids. In: eLS, John Wiley & Sons, Ltd: Chichester. 2013. https://doi.org/10.1002/9780470015902.a0023407.

  • 25.

    Lerner R, Post JM, Ellis SR, Vos DRN, Heeren RMA, Lutz B, et al. Simultaneous lipidomic and transcriptomic profiling in mouse brain punches of acute epileptic seizure model compared to controls. J Lipid Res. 2018;59:283–97.

    CAS 
    PubMed 

    Google Scholar
     

  • 26.

    Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci. 2003;4:873–84.

    CAS 
    PubMed 

    Google Scholar
     

  • 27.

    García C, Palomo-Garo C, Gómez-Gálvez Y, Fernández-Ruiz J. Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia. Br J Pharm. 2016;173:2069–79.


    Google Scholar
     

  • 28.

    Maccarrone M, Rossi S, Bari M, De Chiara V, Fezza F, Musella A, et al. Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. Nat Neurosci. 2008;11:152–9.

    CAS 
    PubMed 

    Google Scholar
     

  • 29.

    Centonze D, Battista N, Rossi S, Mercuri NB, Finazzi-Agrò A, Bernardi G, et al. A critical interaction between dopamine D2 receptors and endocannabinoids mediates the effects of cocaine on striatal gabaergic Transmission. Neuropsychopharmacology. 2004;29:1488–97.

    CAS 
    PubMed 

    Google Scholar
     

  • 30.

    Smart D, Gunthorpe MJ, Jerman JC, Nasir S, Gray J, Muir AI, et al. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br J Pharm. 2000;129:227–30.

    CAS 

    Google Scholar
     

  • 31.

    de Lago E, de Miguel R, Lastres-Becker I, Ramos JA, Fernández-Ruiz J. Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence. Brain Res. 2004;1007:152–9.

    PubMed 

    Google Scholar
     

  • 32.

    Di Marzo V, Lastres-Becker I, Bisogno T, De Petrocellis L, Milone A, Davis JB, et al. Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues. Eur J Pharm. 2001;420:123–31.


    Google Scholar
     

  • 33.

    García MC, Cinquina V, Palomo-Garo C, Rábano A, Fernández-Ruiz J. Identification of CB2 receptors in human nigral neurons that degenerate in Parkinson’s disease. Neurosci Lett. 2015;587:1–4.

    PubMed 

    Google Scholar
     

  • 34.

    Emerging science. https://www.aan.com/conferences-community/annual-meeting/abstracts-and-awards/emerging-science/. Accessed 12 Aug 2018.

  • 35.

    Singer HS. The neurochemistry of Tourette syndrome. In: Martino D, Leckman JF, editors. Tourette syndrome, New York: Oxford University Press; 2013. p. 276–300.

  • 36.

    Gadzicki D, Müller-Vahl KR, Heller D, Ossege S, Nöthen MM, Hebebrand J, et al. Tourette syndrome is not caused by mutations in the central cannabinoid receptor (CNR1) gene. Am J Med Genet B Neuropsychiatr Genet. 2004;127B:97–103.

    PubMed 

    Google Scholar
     

  • 37.

    Berding G, Müller-Vahl K, Schneider U, Gielow P, Fitschen J, Stuhrmann M, et al. [123I]AM281 single-photon emission computed tomography imaging of central cannabinoid CB1 receptors before and after Delta9-tetrahydrocannabinol therapy and whole-body scanning for assessment of radiation dose in Tourette patients. Biol Psychiatry. 2004;55:904–15.

    CAS 
    PubMed 

    Google Scholar
     

  • 38.

    Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M. Endocannabinoid-mediated control of synaptic transmission. Physiol Rev. 2009;89:309–80.

    CAS 
    PubMed 

    Google Scholar
     

  • 39.

    Russo EB. Clinical endocannabinoid deficiency reconsidered: current research supports the theory in migraine, fibromyalgia, irritable bowel, and other treatment-resistant syndromes. Cannabis Cannabinoid Res. 2016;1:154–65.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 40.

    Pisani V, Moschella V, Bari M, Fezza F, Galati S, Bernardi G, et al. Dynamic changes of anandamide in the cerebrospinal fluid of Parkinson’s disease patients. Mov Disord. 2010;25:920–4.

    PubMed 

    Google Scholar
     

  • 41.

    Romigi A, Bari M, Placidi F, Marciani MG, Malaponti M, Torelli F, et al. Cerebrospinal fluid levels of the endocannabinoid anandamide are reduced in patients with untreated newly diagnosed temporal lobe epilepsy. Epilepsia. 2010;51:768–72.

    CAS 
    PubMed 

    Google Scholar
     

  • 42.

    Di Filippo M, Pini LA, Pelliccioli GP, Calabresi P, Sarchielli P. Abnormalities in the cerebrospinal fluid levels of endocannabinoids in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2008;79:1224–9.

    PubMed 

    Google Scholar
     

  • 43.

    Sarchielli P, Pini LA, Coppola F, Rossi C, Baldi A, Mancini ML, et al. Endocannabinoids in chronic migraine: CSF findings suggest a system failure. Neuropsychopharmacology. 2007;32:1384–90.

    CAS 
    PubMed 

    Google Scholar
     

  • 44.

    Neumeister A, Normandin MD, Pietrzak RH, Piomelli D, Zheng M-Q, Gujarro-Anton A, et al. Elevated brain cannabinoid CB1 receptor availability in posttraumatic stress disorder: a positron emission tomography study. Mol Psychiatry. 2013;18:1034–40.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 45.

    Yi B, Nichiporuk I, Nicolas M, Schneider S, Feuerecker M, Vassilieva G, et al. Reductions in circulating endocannabinoid 2-arachidonoylglycerol levels in healthy human subjects exposed to chronic stressors. Prog Neuropsychopharmacol Biol Psychiatry. 2016;67:92–7.

    CAS 
    PubMed 

    Google Scholar
     

  • 46.

    Hoekstra PJ, Dietrich A, Edwards MJ, Elamin I, Martino D. Environmental factors in Tourette syndrome. Neurosci Biobehav Rev. 2013;37:1040–9.

    PubMed 

    Google Scholar
     

  • 47.

    Volkow ND, Hampson AJ, Baler RD. Don’t worry, be happy: endocannabinoids and cannabis at the intersection of stress and reward. Annu Rev Pharm Toxicol. 2017;57:285–308.

    CAS 

    Google Scholar
     

  • 48.

    Cooper RE, Williams E, Seegobin S, Tye C, Kuntsi J, Asherson P. Cannabinoids in attention-deficit/hyperactivity disorder: a randomised-controlled trial. Eur Neuropsychopharmacol. 2017;27:795–808.

    CAS 
    PubMed 

    Google Scholar
     

  • 49.

    Centonze D, Bari M, Di Michele B, Rossi S, Gasperi V, Pasini A, et al. Altered anandamide degradation in attention-deficit/hyperactivity disorder. Neurology. 2009;72:1526–7.

    CAS 
    PubMed 

    Google Scholar
     

  • 50.

    Walker LE, Griffiths MJ, McGill F, Lewthwaite P, Sills GJ, Jorgensen A, et al. A comparison of HMGB1 concentrations between cerebrospinal fluid and blood in patients with neurological disease. Biomarkers. 2017;22:635–42.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 51.

    Rubino T, Parolaro D. Sexually dimorphic effects of cannabinoid compounds on emotion and cognition. Front Behav Neurosci. 2011;5:64.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 52.

    Baumeister D, Eich W, Lerner R, Lutz B, Bindila L, Tesarz J. Plasma parameters of the endocannabinoid system are unaltered in fibromyalgia. Psychother Psychosom. 2018;87:377–9.

    PubMed 

    Google Scholar
     

  • Source link

    LEAVE A REPLY

    Please enter your comment!
    Please enter your name here